Recurrent drug eluting stent, in-stent restenosis (DES-ISR): Epidemiology, pathophysiology & treatment Article

Full Text via DOI: 10.1016/j.pcad.2024.12.003 Web of Science: 001428263400001

Cited authors

  • Gupta A, Maitas O, Patel RAG

Abstract

  • Coronary artery in-stent restenosis (ISR) is driven by neointimal hyperplasia and neo-atherosclerosis in previously placed stents. Drug eluting stents (DES) have been adopted as first line therapy for the initial episode of ISR. However, recurrent ISR has limited durable salvage options. In this article we review the pathophysiology, incidence, and management options of recurrent DES- ISR.

Publication date

  • 2025

Published in

International Standard Serial Number (ISSN)

  • 0033-0620

Number of pages

  • 7

Start page

  • 68

End page

  • 74

Volume

  • 88